{"name":"Blueprint Medicines","slug":"blueprint","ticker":"BPMC","exchange":"NASDAQ","domain":"blueprintmedicines.com","description":"Blueprint Medicines is a precision oncology and rare disease company focused on developing targeted therapies for genetically defined diseases. The company's pipeline includes several promising candidates, including avapritinib and pralsetinib. With a strong market position and a growing portfolio of approved products, Blueprint Medicines is well-positioned for continued growth and success.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Kate Haviland","sector":"Precision Oncology / Rare Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.8B","metrics":{"revenue":560000000,"revenueGrowth":1216.1,"grossMargin":0,"rdSpend":341433000,"netIncome":-67089000,"cash":1179813000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Ayvakit first approved","drug":"Ayvakit","drugSlug":"avapritinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Avapritinib patent cliff ($1.1B at risk)","drug":"Avapritinib","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Pralsetinib patent cliff ($500M at risk)","drug":"Pralsetinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ayvakit","genericName":"AVAPRITINIB","slug":"avapritinib","indication":"Gastrointestinal stromal tumor","status":"marketed"},{"name":"BLU-808","genericName":"BLU-808","slug":"blu-808","indication":"Gastrointestinal stromal tumor (GIST)","status":"phase_2"}]}],"pipeline":[{"name":"Ayvakit","genericName":"AVAPRITINIB","slug":"avapritinib","phase":"marketed","mechanism":"Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells.","indications":["Gastrointestinal stromal tumor","Systemic mast cell disease"],"catalyst":""},{"name":"BLU-808","genericName":"BLU-808","slug":"blu-808","phase":"phase_2","mechanism":"BLU-808 is a potent and selective KIT inhibitor.","indications":["Gastrointestinal stromal tumor (GIST)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"The company reported net product revenue of $1.1 billion for the full year 2023, representing a 25% increase from the prior year.","drugName":"","sentiment":"positive"},{"date":"2023-12-15","type":"deal","headline":"Blueprint Medicines Announces Collaboration with Merck to Develop and Commercialize Avapritinib in Combination with Merck's KEYTRUDA","summary":"The collaboration aims to evaluate the combination of avapritinib and KEYTRUDA in patients with gastrointestinal stromal tumor (GIST) and other cancers.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves Avapritinib for the Treatment of Gastrointestinal Stromal Tumor (GIST)","summary":"The approval marks the first indication for avapritinib, a targeted therapy for patients with GIST who have a PDGFRA exon 18 mutation.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNaWd5Zm9HZXNBSExTUEdDdm9KbFZtR1lnMUlreUJGSFZGbnE1cjQ5MEJkeExGdFFUdWs1bWNxSFNuTmxZQ20wanRZbjhPVzhKaVZ5U2FEN1h0cVdRUEQyc0FRQmpDSGFwRWJlYlZSYmgwd1FmTURDM09rb3Bid1BTT2VwcXhfVWNPTUZhZWI1SFoxWGVqUGh3MUt3?oc=5","date":"2025-07-21","type":"pipeline","source":"Yahoo Finance","summary":"Sanofi concludes Blueprint Medicines acquisition - Yahoo Finance","headline":"Sanofi concludes Blueprint Medicines acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQkxfcHVKZG9JZmstcWxfcGJ1Z0tSeFhKck90dFBWYVFDX0Z1YmhmSG1ZbnNBTElJNV9SazdVbDFqZ3ZKb1EycmYtRmwxQjdJSHNXcmxsX3lJTjdBTWRqbTRxTTQwb3pDMEVVRWRQZFVnS3Y2MFpDY3U1eHFzSHNnbEpfb2tyNklWbmRCQzVSUUFlU0kxX1J2LU85bVVVV0QySFJEdUxoek5fcm9WRkxIMjgwb3VSVnA4?oc=5","date":"2025-06-18","type":"deal","source":"Seeking Alpha","summary":"Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade (BPMC) - Seeking Alpha","headline":"Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade (BPMC)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-12","type":"trial","source":"PR Newswire","summary":"Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - P","headline":"Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Ter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOV3hXbi11LUp1ajA5QmZVZk9TVU53dTVrUFJTMU5FaEptQUFWQXFUZDZuTnI2a0oxai1HMkM1Y0lKX1oxWV80TzVfUUV2ZlB4UVRjcXU4ejVvVGRWNGtKczZMRnRKMjJnOWN0TWlDUjZCOGdHTmYxVDF2T2lhZkMxU2o4QVotYzZhVndpcFdxbldzWGxzRXg1Y0pJeVlob2FyR3Rza0h4NmxUVk5UdVE?oc=5","date":"2025-06-03","type":"deal","source":"The Business Journals","summary":"Sanofi to buy Blueprint Medicines for $9.1B - The Business Journals","headline":"Sanofi to buy Blueprint Medicines for $9.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNaXFIVHdtZGgwcUo1ZnJxbFVjQ1JGUnpwYmpndjhLTS10ZW5nN3RzZ0U0UUhhaE9RMUcteUJReS10QkM2SFF2bXBidzFpQnhNLXZ4ejVDQ09sSGdFVEdNTHROQ016aU1tNDFMQ1A3WGd4Y1p1ckkyUWw0NW9UQ3JxOFBtTzMtNG12XzVJWlNHemhiR1Qzd1dyMzRMVmR2RWtVNFo3VkdPMWkxeThkZmY3Yl82OVI?oc=5","date":"2025-06-02","type":"pipeline","source":"Investopedia","summary":"Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover - Investopedia","headline":"Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNa2hHZmEwSjNrSng0Nl9lTXh1bkNlQ3M0YzBUSUN0Y2NscHVuZExZbzk4Nmo2bUZ3WFJHa0R4N1NqVm5NTzNpODZaM0hvc1RpaTV3djF3QjYyNlFqT0w1TDBaLVRuT3k4QmVvMld5bWlVa3MxRmNRQXpRVTRWb2FYa2xGZFpaR3hhV09IRXdxQUkwM1BMVkFLbDNLR1FVR2o4Qm15ZGk3U2E5SVQ0VmF6VVY1RndmSjJnNnkxak9RWTR3Zw?oc=5","date":"2025-06-02","type":"deal","source":"Reuters","summary":"Sanofi to buy US biopharma group Blueprint for up to $9.5 billion - Reuters","headline":"Sanofi to buy US biopharma group Blueprint for up to $9.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPbXFKZ0xmUVgzS0ZQQTROSmVXN05uNVd2aXFFSVY5Qi1aYjV3a1BfZGVsNjhGSnU5SVVwQ3R3NDg1RTZKSnlmQ1E0ajhqc0FUc1E3aEtTdGVEQVR1X2tQWEgtSFVTblNNQ1ZpbVhHM1ZrM2pLSFpxTkFneXRfRFNaWmhlZGtjRWtWLVZ5b0pHc2lDeE9vRTZFTEo4ektSYWM?oc=5","date":"2025-06-02","type":"pipeline","source":"Fierce Pharma","summary":"With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B - Fierce Pharma","headline":"With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbjBrTTZpNWJ5WXl6M2J5cmQydmRXMXMweWZKYS1fTktfaFdQdGxEQkNmZ1VEVGpkbTlzRGJ5ZGtVTFFvY3JiNFoyWG5RQmt6RFJFTUlmbGN1R29Yd0N4ZmozR3lCX3RHNkNQdDloYmpzcHcwVFRDbkxLR1hlczQxeDlWSmNpb0NzYkxrcTRBeWhNNDlLaGR3ZmZjaFdFaXNfd3JHWVl5amxSTWFyNC05RU16QQ?oc=5","date":"2025-06-02","type":"deal","source":"bloomberg.com","summary":"Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - bloomberg.com","headline":"Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxORmtsZVgtcHNpaTNVR1o4RzV6bXp1dkpwR2x5VzJPMG1TNC1YRDRkM1RDNE13cldSU2V6TWNIV3AyZi0tV1ZjQnFyWk9vX01FQnJWbGFiakEtTEFHQXRTbU1LRUdGSGNUVUFtZWxTUXo0Uy01Vkhhb1ZabWpZRkoweXdMd1p0amVVOXUtQjZ6MA?oc=5","date":"2025-06-02","type":"deal","source":"Barron's","summary":"Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barron's","headline":"Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOSDdiMndQT2Y1YmwtdU1Bd24yTjVNSnlCTFJxbUdZS1Z3TzJkc0VrS0Y4UjdjQS1xektiSTBNNGV0OWZqZU4wSGRNV0IzZWlBR0pQNWVCVnQtcmIzbXN6VzZjMnZNTFJsYVVuc1ZFbzJrY0lUMDBtdHNwOWNHMVRDWkREd3hBYjl1T1BoLS1jbFdnU2ZkMm4yemRB?oc=5","date":"2025-06-02","type":"deal","source":"The Globe and Mail","summary":"France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail","headline":"France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYUdCTHR1amdVWFVSemdqUFRUZ2ptdS00eFdua2ltTWdkT3RzZE9zcmpURG52MVcyVjN5RmY2N0dYdXQ4cmtER1lrQUUzSTRpbEEzQ0lXaThodnFmSWpSSkc0SjdGMFl0OElaczd1U19rY2ZKaURrVms0SFlCeFN2NVpNT2F1YUpBOW5z?oc=5","date":"2025-06-02","type":"deal","source":"Yahoo Finance","summary":"M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal - Yahoo Finance","headline":"M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPU0lfb3JuanBtUjRDM1dtTmxrdG1idXpCNFVXaUcwUVdEdlNGTDhjYzU0ZGx0ekxval9YWkJ0VWFyOEJLUUtGdU9aSDFPa1BOVVE5c3QxVWhpREdxVTBjQ3JLS08wdUJid3praE55NDNXeGpfWUd3YlA5T0tpVi1CM3RkUDJzNXU0cE9CZHlXdzJmTU4yY3pQWGxnUVhXOVhocU9WUWE2T2FPRHhzLW1kLUQ0UmpVX0tuSmJuNzJucE1OMGJla1V5QVdFbjF3VVhyQnJkNHU4RklIQUh1ZGJGbzNjWWN5aldTY0tiZFNEREtFVnZWRm5BaTFMZXNLcEg2MVZDWg?oc=5","date":"2022-06-30","type":"deal","source":"Sixth Street","summary":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma - Sixth Street","headline":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Roya","sentiment":"neutral"}],"patents":[{"drugName":"Avapritinib","drugSlug":"avapritinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Pralsetinib","drugSlug":"pralsetinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":500000000}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Novartis","Pfizer","Merck"],"therapeuticFocus":["Precision Oncology","Rare Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":21426000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":21426000,"period":"2017-12-31"},{"value":1628000,"period":"2017-12-31"},{"value":8068000,"period":"2017-09-30"},{"value":5890000,"period":"2017-06-30"},{"value":5840000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":341433000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-67089000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1179813000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}